Experts map “post-jab” future in GSK-sponsored panel discussion
Read more - Experts map “post-jab” future in GSK-sponsored panel discussion Read more
Press releases
These press releases are intended for business journalists and analysts/investors
First monoclonal antibody treatment approved for COVID-19 in Australia
Read more - First monoclonal antibody treatment approved for COVID-19 in Australia Read more
New shingles vaccine now available in Australia
Read more - New shingles vaccine now available in Australia Read more
GSK Australia reports 2020 results to ASIC, May 2021
Read more - GSK Australia reports 2020 results to ASIC, May 2021 Read more
GSK Supports the Uluru Statement from the Heart March 2021
Read more - GSK Supports the Uluru Statement from the Heart March 2021 Read more
Triathlete turned scientist wins major research award for uncovering potential obesity and diabetes treatment
Following decision announced in July, GSK confirms Boronia manufacturing site to close at end of 2022
GSK welcomes new Meningococcal B program to help protect those most at risk
GSK Australia today welcomed the addition of Meningococcal B (MenB) vaccination for Aboriginal and Torres Strait Islander infants to the National Immunisation Program (NIP)1 as well as people of all ages with some medical conditions that increase their risk of Invasive Meningococcal Disease (IMD).
Read more - GSK welcomes new Meningococcal B program to help protect those most at risk Read more
Greater flexibility for Australians with severe asthma with reimbursement of at-home, self-administration delivery of NUCALA® (mepolizumab)
GSK Australia today announced that a new pre-filled pen (autoinjector) for the self-administration of its targeted therapy for severe eosinophilic asthma patients, NUCALA (mepolizumab), will be reimbursed by the Pharmaceutical Benefits Scheme (PBS) from 1 June 2020.
GSK Australia reports 2019 results (excluding Consumer Healthcare) to ASIC
GlaxoSmithKline (GSK) Australia has reported its 2019 results to the Australian Securities and Investment Commission (ASIC) for its pharmaceuticals and vaccines business, and ViiV Healthcare Australia (a joint venture with Pfizer and Shionogi focused on HIV). GSK Australia’s Consumer Healthcare business will report separately in the coming months.
Read more - GSK Australia reports 2019 results (excluding Consumer Healthcare) to ASIC Read more
